AbCellera Biologics Inc.
ABCL
Jodie situation report
AbCellera Biologics Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 5 of 8 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 5 directly disclosed connections are confirming.
- Participation spreads to CLNN, PACB, VERU.
- Capital-flow agreement rises above 55%.
- TXG remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.
Who this business touches
The relationships behind ABCL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BRKRBruker CorporationpartnerMay 11, 2026 ▾
“For example, we were engaged in a lawsuit with Bruker Cellular Analysis (“Bruker”) based upon our allegations of its infringement of our intellectual property rights that we settled in December 2025.”
LINELineage, Inc.investeeMay 11, 2026 ▾
“Through our acquisition of Lineage, we obtained patents and patent applications directed toward immune-repertoire sequencing.”
Depended on by
RLYBRallybio CorporationpartnerAug 7, 2025 ▾
“This multi-year, multi-target collaboration will combine AbCellera Biologics Inc.'s ("AbCellera's") antibody discovery engine with our clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapi…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ABCL is currently a Early Follower in the organic co-movement group Gene Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.